Differential effects of specific cathepsin S inhibition in biocompartments from patients with primary Sjögren syndrome

EULAR ^® 2020

Sjögren’s Syndrome

Further Publications Rheumatology

Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial

Ann Rheum Dis

Felten R, Devauchelle-Pensec V, Seror R, Duffau P, Saadoun D, Hachulla E, Pierre Yves H, Salliot C, Perdriger A, Morel J, Mékinian A, Vittecoq O, Berthelot JM, Dernis E, Le Guern V, Dieudé P, Larroche C, Richez C, Martin T, Zarnitsky C, Blaison G, Kieffer P, Maurier F, Dellal A, Rist S, Andres E, Contis A, Chatelus E, Sordet C, Sibilia J, Arnold C, Tawk MY, Aberkane O, Holterbach L, Cacoub P, Saraux A, Mariette X, Meyer N, Gottenberg JE

doi: 10.1136/annrheumdis-2020-218467

Autoimmune Disease

Shared gut, but distinct oral microbiota composition in primary Sjögren's syndrome and systemic lupus erythematosus

J Autoimmun.

van der Meulen TA, Harmsen HJM, Vila AV, Kurilshikov A, Liefers SC, Zhernakova A, Fu J, Wijmenga C, Weersma RK, de Leeuw K, Bootsma H, Spijkervet FKL, Vissink A, Kroese FGM

doi: 10.1016/j.jaut.2018.10.009.

Autoimmune Disease

Arthritis in primary Sjögren's syndrome: Characteristics, outcome and treatment from French multicenter retrospective study

Autoimmun Rev.

Mirouse A, Seror R, Vicaut E, Mariette X, Dougados M, Fauchais AL, Deroux A, Dellal A, Costedoat-Chalumeau N, Denis G, Sellam J, Arlet JB, Lavigne C, Urbanski G, Fischer-Dumont D, Diallo A, Fain O, Mékinian A; Club Rhumatismes Inflammation and SNFMI

doi: 10.1016/j.autrev.2018.06.015.

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

Incorporation of salivary gland ultrasonography into the ACR-EULAR criteria for primary Sjögren's syndrome

Arthritis Care Res (Hoboken).

van Nimwegen JF, Mossel E, Delli K, van Ginkel MS, Stel AJ, Kroese FGM, Spijkervet FKL, Vissink A, Arends S, Bootsma H

doi: 10.1002/acr.24017.

Further Publications Rheumatology

Patients with early-onset primary Sjögren's syndrome have distinctive clinical manifestations and circulating lymphocyte profiles

Rheumatology (Oxford)

Wei L, Zhifei X, Xiaoran N, Meilu L, Yang L, Yixuan L, Xiuying R, Yashuang S, Jingjing C, Shaoying G, Liu Y, Lijun S, Fengxiao Z, Wen Z

doi: 10.1093/rheumatology/keab367

Autoimmune Disease

Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial

Ann Rheum Dis

Baer AN, Gottenberg JE, St Clair EW, Sumida T, Takeuchi T, Seror R, Foulks G, Nys M, Mukherjee S, Wong R, Ray N, Bootsma H

doi: 10.1136/annrheumdis-2020-218599

Autoimmune Disease

EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies

Ann Rheum Dis.

Ramos-Casals M, Brito-Zerón P, Bombardieri S, Bootsma H, De Vita S, Dörner T, Fisher BA, Gottenberg JE, Hernandez-Molina G, Kocher A, Kostov B, Kruize AA, Mandl T, Ng WF, Retamozo S, Seror R, Shoenfeld Y, Sisó-Almirall A, Tzioufas AG, Vitali C, Bowman S, Mariette X, EULAR-Sjögren Syndrome Task Force Group.

doi: 10.1136/

Further Publications Immunology

HSCT is effective in patients with PSTPIP1-associated myeloid-related proteinemia inflammatory (PAMI) syndrome

J Allergy Clin Immunol

Laberko A, Burlakov V, Maier S, Abinun M, Skinner R, Kozlova A, Suri D, Lehmberg K, Müller I, Balashov D, Novichkova G, Holzinger D, Gennery AR, Shcherbina A

doi: 10.1016/j.jaci.2020.11.043

Related content

Sjögren’s Syndrome

Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial

Shared gut, but distinct oral microbiota composition in primary Sjögren's syndrome and systemic lupus erythematosus

Arthritis in primary Sjögren's syndrome: Characteristics, outcome and treatment from French multicenter retrospective study

Incorporation of salivary gland ultrasonography into the ACR-EULAR criteria for primary Sjögren's syndrome

Patients with early-onset primary Sjögren's syndrome have distinctive clinical manifestations and circulating lymphocyte profiles

Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial

EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies

HSCT is effective in patients with PSTPIP1-associated myeloid-related proteinemia inflammatory (PAMI) syndrome